Free Trial

China Pharma (CPHI) Competitors

China Pharma logo
$1.82 -0.06 (-2.98%)
Closing price 10/17/2025 03:59 PM Eastern
Extended Trading
$1.83 +0.01 (+0.38%)
As of 10/17/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CPHI vs. ALVR, MTVA, NNVC, CASI, AYTU, MBRX, ALLR, PCSA, CTXR, and RLYB

Should you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include AlloVir (ALVR), MetaVia (MTVA), NanoViricides (NNVC), CASI Pharmaceuticals (CASI), Aytu BioPharma (AYTU), Moleculin Biotech (MBRX), Allarity Therapeutics (ALLR), Heatwurx (PCSA), Citius Pharmaceuticals (CTXR), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry.

China Pharma vs. Its Competitors

China Pharma (NYSE:CPHI) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

China Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.

66.1% of AlloVir shares are held by institutional investors. 17.3% of China Pharma shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

China Pharma has higher revenue and earnings than AlloVir.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Pharma$4.40M1.35-$3.08MN/AN/A
AlloVirN/AN/A-$190.42M-$20.23-0.23

AlloVir has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat AlloVir's return on equity.

Company Net Margins Return on Equity Return on Assets
China Pharma-85.56% -63.93% -31.42%
AlloVir N/A -71.03%-61.27%

In the previous week, AlloVir had 1 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for AlloVir and 1 mentions for China Pharma. AlloVir's average media sentiment score of 0.00 beat China Pharma's score of -1.00 indicating that AlloVir is being referred to more favorably in the news media.

Company Overall Sentiment
China Pharma Negative
AlloVir Neutral

Summary

China Pharma and AlloVir tied by winning 5 of the 10 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CPHI vs. The Competition

MetricChina PharmaPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$5.95M$1.08B$6.15B$21.82B
Dividend YieldN/A4.84%5.72%3.62%
P/E RatioN/A1.3085.7032.43
Price / Sales1.3529.96612.9260.43
Price / CashN/A17.6325.8218.06
Price / Book2.618.0712.224.59
Net Income-$3.08M-$7.36M$3.33B$1.01B
7 Day Performance0.22%-1.73%1.17%1.31%
1 Month Performance-8.11%28.41%6.85%-0.93%
1 Year Performance-92.67%-12.09%58.93%9.51%

China Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CPHI
China Pharma
0.1489 of 5 stars
$1.82
-3.0%
N/A-92.4%$5.95M$4.40M0.00250Negative News
Short Interest ↑
ALVR
AlloVir
N/A$4.76
+7.0%
N/A-74.0%$24.01MN/A-0.24110News Coverage
High Trading Volume
MTVA
MetaVia
1.6318 of 5 stars
$1.02
+2.9%
$7.50
+635.3%
N/A$23.98MN/A0.008Gap Down
NNVC
NanoViricides
0.8216 of 5 stars
$1.35
-0.7%
N/A+2.0%$23.53MN/A-1.8720News Coverage
Short Interest ↓
CASI
CASI Pharmaceuticals
3.5593 of 5 stars
$1.81
-4.2%
$4.00
+121.0%
-68.9%$23.25M$31.56M-0.63180Analyst Forecast
AYTU
Aytu BioPharma
3.3018 of 5 stars
$2.38
+1.7%
$9.17
+285.2%
+0.0%$23.19M$66.38M-0.84160Analyst Forecast
MBRX
Moleculin Biotech
1.7009 of 5 stars
$0.50
+5.9%
$4.00
+708.1%
-80.4%$23.14MN/A0.0020Gap Down
ALLR
Allarity Therapeutics
2.2089 of 5 stars
$1.52
-0.7%
$9.25
+508.6%
-16.8%$22.22MN/A0.0010Gap Down
PCSA
Heatwurx
2.4601 of 5 stars
$0.40
-10.2%
$1.00
+152.5%
-77.5%$22.21MN/A-0.1720Negative News
Short Interest ↑
CTXR
Citius Pharmaceuticals
2.6366 of 5 stars
$1.30
flat
$53.00
+3,976.9%
-85.2%$22.12MN/A0.0020News Coverage
RLYB
Rallybio
2.7976 of 5 stars
$0.53
+1.3%
$5.00
+834.9%
-52.2%$22.07M$761K-0.5740Gap Down

Related Companies and Tools


This page (NYSE:CPHI) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners